Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Aug 11;15(16):3533.
doi: 10.3390/nu15163533.

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study

Daniel Keizman  1 , Moshe Frenkel  2 , Avivit Peer  2 , Eli Rosenbaum  3 , David Sarid  1 , Ilan Leibovitch  4 , Roy Mano  5 , Ofer Yossepowitch  5 , Ido Wolf  1 , Ravit Geva  1 , David Margel  6 , Keren Rouvinov  7 , Anat Stern  8 , Hadas Dresler  9 , Igal Kushnir  10 , Isaac Eliaz  8
Affiliations
Clinical Trial

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study

Daniel Keizman et al. Nutrients. .

Abstract

The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol®-Modified citrus pectin (P-MCP) is a food supplement categorized as GRAS (Generally Recognized As Safe) by the FDA. It is a competitive inhibitor of the galectin-3 protein, which is involved in cancer pathogenesis. In an early report of the present phase 2 study, P-MCP treatment for 6 months led to prostate-specific antigen doubling time (PSADT) improvement in 75% of patients with BRPC-M0. Herein, we report the second long-term treatment phase of an additional 12 months of P-MCP therapy (4.8 g × 3/day orally) in patients without disease progression after the initial 6 months of therapy. Of the 46 patients that entered the second treatment phase, 7 patients withdrew consent and decided to continue therapy out of pocket, and 39 initiated the second treatment phase. After a total of 18 months of P-MCP treatment, 85% (n = 33) had a durable long-term response, with 62% (n = 24) showing decreased/stable PSA, 90% (n = 35) PSADT improvement, and all with negative scans. No patient had grade 3/4 toxicity. In conclusion, P-MCP may have long-term durable efficacy and is safe in BRPC-M0.

Keywords: modified citrus pectin; non-metastatic biochemically relapsed prostate cancer.

PubMed Disclaimer

Conflict of interest statement

I.E. discloses being the developer of the sponsoring dietary supplement company but holds no ownership in the company. The other authors declare no potential conflict of interest.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Disease progression status after 18 months of PectaSol®-Modified Citrus Pectin (P-MCP) therapy.
Figure 3
Figure 3
The number of patients in each PSADT risk group at baseline and after 18 months of PectaSol®-Modified Citrus Pectin (P-MCP) therapy.
See this image and copyright information in PMC

References

    1. Gandaglia G., Leni R., Bray F., Fleshner N., Freedland S.J., Kibel A., Stattin P., Van Poppel H., La Vecchia C. Epidemiology and Prevention of Prostate Cancer. Eur. Urol. Oncol. 2021;4:877–892. doi: 10.1016/j.euo.2021.09.006. - DOI - PubMed
    1. Boettcher A.N., Usman A., Morgans A., VanderWeele D.J., Sosman J., Wu J.D. Past, Current, and Future of Immunotherapies for Prostate Cancer. Front. Oncol. 2019;9:884. doi: 10.3389/fonc.2019.00884. - DOI - PMC - PubMed
    1. Rawla P. Epidemiology of Prostate Cancer. World J. Oncol. 2019;10:63–89. doi: 10.14740/wjon1191. - DOI - PMC - PubMed
    1. Wang L., Lu B., He M., Wang Y., Wang Z., Du L. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front. Public Health. 2022;10:811044. doi: 10.3389/fpubh.2022.811044. - DOI - PMC - PubMed
    1. Zhai Z., Zheng Y., Li N., Deng Y., Zhou L., Tian T., Yang S., Hao Q., Song D., Wu Y., et al. Incidence and Disease Burden of Prostate Cancer from 1990 to 2017: Results from the Global Burden of Disease Study 2017. Cancer. 2020;126:1969–1978. doi: 10.1002/cncr.32733. - DOI - PubMed

Publication types